Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 929-934

  Lupo, J ^a,b   Germi, R ^a,b   Semenova, T ^a   Buisson, M ^a,b   Seigneurin, J M ^a   Morand, P ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOANALYSIS; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIAISON IMMUNOASSAY; MAJOR CLINICAL STUDY; NONHUMAN; PERFORMANCE MEASUREMENT SYSTEM; PRESCHOOL CHILD; PRIMARY INFECTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIDAS IMMUNOASSAY; VIRUS DETECTION; VIRUS DIAGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; AUTOMATION; CHILD; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; VIROLOGY; YOUNG ADULT;

EID: 84861744839     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00100-12     Document Type: Article

References (36)

1. Bauer G. 2001. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin. Lab. 47:223-230. (Pubitemid 32492869)
2. Berth M, Bosmans E. 2009. Acute parvovirus B19 infection frequently causes false-positive results in Epstein-Barr virus- and herpes simplex virus-specific immunoglobulinMdeterminations done on the Liaison platform. Clin. Vaccine Immunol. 16:372-375.
3. Berth M, Bosmans E. 2010. Comparison of three automated immunoassay methods for the determination of Epstein-Barr virus-specific immunoglobulin M. Clin. Vaccine Immunol. 17:559 -563.
4. Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Beito EM. 2008. Evaluation of a multiplex flow immunoassay for detection of epstein-barr virus-specific antibodies. Clin. Vaccine Immunol. 15:1410-1413.
5. Bravo D, et al. 2009. Evaluation of an immunofiltration assay that detects immunoglobulin M antibodies against the ZEBRA protein for the diagnosis of Epstein-Barr virus infectious mononucleosis in immunocompetent patients. Clin. Vaccine Immunol. 16:885-888.
6. Bruu AL, et al. 2000. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin. Diagn. Lab. Immunol. 7:451-456.
7. Buisson M, et al. 1999. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J. Clin. Microbiol. 37:2709-2714. (Pubitemid 29337305)
8. Clinical and Laboratory Standards Institute. 2008. User protocol for evaluation of qualitative test performance; approved guideline-second edition. Document EP12-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Debyser Z, Reynders M, Goubau P, Desmyter J. 1997. Comparative evaluation of three ELISA techniques and an indirect immunofluorescence assay for the serological diagnosis of Epstein-Barr virus infection. Clin. Diagn. Virol. 8:71-81. (Pubitemid 27283266)
10. de Ory F, Guisasola ME, Sanz JC, Garcia-Bermejo I. 2011. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin. Vaccine Immunol. 18:444-448.
11. De Paschale M, et al. 2009. Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern. J. Med. Virol. 81:325-331.
12. De Paschale M, et al. 2010. Search for anti-EA(D) antibodies in subjects with an "isolated VCA IgG" pattern. Int. J. Microbiol. 2010:695104. doi:10.1155/2010/695104.
13. Devanthéry O, Meylan P. 2010. Comparison of a multiplexed bead-based assay with an immunofluorescence and an enzyme-immuno assay for the assessment of Epstein-Barr virus serologic status. Clin. Microbiol. Infect. 16:1776-1782.
14. García T, Tormo N, Gimeno C, Navarro D. 2008. Assessment of Epstein-Barr virus (EBV) serostatus by enzyme immunoassays: plausibility of the isolated EBNA-1 IgG positive serological profile. J. Infect. 57:351-353.
15. Gärtner BC, et al. 2003. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol. 10:78-82. (Pubitemid 36133833)
16. Ghinoiu M, et al. 2009. Acute hepatitis E infection associated with a false-positive serology against Epstein-Barr virus. Eur. J. Gastroenterol. Hepatol. 21:1433-1435.
17. Gu AD, et al. 2009. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J. Transl. Med. 7:73. doi:10.1186/1479-5876-7-73.
18. Gulley ML, Tang W. 2008. Laboratory assays for Epstein-Barr virusrelated disease. J. Mol. Diagn. 10:279-292. (Pubitemid 352022708)
19. Gutiérrez J, Vergara MJ, Piedrola G, Maroto MC. 1999. Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA. J. Clin. Lab. Anal. 13:65-68. (Pubitemid 29104626)
20. Hess RD. 2004. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J. Clin. Microbiol. 42:3381-3387. (Pubitemid 39045655)
21. Humar A, Michaels M. 2006. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant. 6:262-274. (Pubitemid 43382161)
22. Hurt C, Tammaro D. 2007. Diagnostic evaluation of mononucleosis-like illnesses. Am. J. Med. 120:911e1-911e8.
23. Kleines M, Scheithauer S, Ritter K, Hausler M. 2006. Sensitivity of the Enzygnost anti-EBV/IgG for the determination of the Epstein-Barr virus immune status in pediatric patients. Diagn. Microbiol. Infect. Dis. 55:247-249. (Pubitemid 43928404)
24. Klutts JS, Ford BA, Perez NR, Gronowski AM. 2009. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J. Clin. Microbiol. 47:3204-3210.
25. Lindecker V, Burg E, Maisonneuve P, Seigneurin JM. 2001. EBV serology and quality control in the year 2000. Ann. Biol. Clin. (Paris) 59(Spec No):34-36. (In French.) (Pubitemid 32977400)
26. Luzuriaga K, Sullivan JL. 2010. Infectious mononucleosis. N. Engl. J. Med. 362:1993-2000.
27. Martins TB, Litwin CM, Hill HR. 2008. Evaluation of a multiplex fluorescent microsphere immunoassay for the determination of Epstein-Barr virus serologic status. Am. J. Clin. Pathol. 129:34-41. (Pubitemid 352038592)
28. Nystad TW, Myrmel H. 2007. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J. Clin. Virol. 38:292-297. (Pubitemid 46413995)
29. Odumade OA, Hogquist KA, Balfour HH, Jr. 2011. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol. Rev. 24:193-209.
30. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. 2009. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Clin. Vaccine Immunol. 16:706-711.
31. Rea TD, Ashley RL, Russo JE, Buchwald DS. 2002. A systematic study of Epstein-Barr virus serologic assays following acute infection. Am. J. Clin. Pathol. 117:156-161. (Pubitemid 34052486)
32. Schaade L, Kleines M, Hausler M. 2001. Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein- Barr virus infections in childhood. J. Clin. Microbiol. 39:3902-3905. (Pubitemid 33029758)
33. Sener AG, Afsar I, Pinar E. 2009. Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state. J. Virol. Methods 159:300-302.
34. Thorley-Lawson DA, Gross A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337. (Pubitemid 38375368)
35. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. (Pubitemid 39331148)
36. Zaia J, et al. 2009. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 44:471- 482.